Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 50 versus JOBEVNE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 50 versus JOBEVNE.
DURAGESIC-50 vs JOBEVNE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
JOBEVNE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine receptor, reducing inflammatory signaling.
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
100 mg intravenously every 12 hours.
None Documented
None Documented
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Terminal half-life: 12-15 hours; clinical context: supports twice-daily dosing in most patients
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic